Australia Health

Atomo Diagnostics (ASX:AT1) announced a new purchase order valued at $416,000 for its HIV Self-Tests, destined for a major health initiative in Africa.

ResMed's (ASX:RMD) revenue for the second quarter to December 2025 climbed 11% to $1.4 billion, reflecting a 9% increase on a constant currency basis.

Mayne Pharma (ASX:MYX) is set to return to the Supreme Court of New South Wales next month to recover legal costs from its failed $672 million takeover by US-based Cosette Pharmaceuticals.

Imricor Medical Systems (ASX:IMR) has achieved a major regulatory milestone with the US Food and Drug Administration granting 510(k) clearance for its NorthStar Mapping System.

Clinical-stage biopharmaceutical leader Radiopharm Theranostics (ASX:RAD) has released its financial results for the first half of fiscal 2026, reporting a cash position of $34.5 million and a series of significant clinical breakthroughs.

Rhythm Biosciences (ASX:RHY) has secured a strategic partnership with CancerIQ, a US digital oncology platform.

Mesoblast (ASX:MSB) reported encouraging real-world outcomes for its FDA-approved therapy Ryoncil (remestemcel-L-rknd) in children with steroid-refractory acute graft-versus-host disease.

Monash IVF Group (ASX:MVF) announced the resignation of its CFO and company secretary, Malik Jainudeen.

Macquarie Health, one of Australia's largest privately owned hospital groups, is preparing to terminate contracts with dozens of private health insurers.

Firebrick Pharma (ASX:FRE) has launched its first international product, Nasodine throat spray, in Singapore.

Algorae Pharmaceuticals (ASX:1AI) has secured a $3 million receivables-based working capital facility with ScotPac Business Finance.

Clinical-stage biotech company Noxopharm (ASX:NOX) has completed the HERACLES clinical trial.